Pentan-3-yl 2-(2,5-dimethylfuran-3-yl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(2-pyridin-2-ylethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: Pentan-3-yl 2-(2,5-dimethylfuran-3-yl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(2-pyridin-2-ylethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylate
• 化学式: C₃₄H₃₈FN₅O₄
• 分子量: 599.7
• InChiKey: NVJDXQUSXGIFBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  44
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  93.7
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
  申请人：——

  公开号：US20020177556A1

  公开（公告）日：2002-11-28

  The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.

  本发明涉及用不会导致阉割的中等剂量 LHRH 拮抗剂治疗痴呆症和阿尔茨海默病等神经退行性疾病。首选的 LHRH 拮抗剂是西曲瑞克。
• TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISEASES WITH INTERMEDIATE DOSES OF LHRH ANTAGONISTS
  申请人：Zentaris GmbH

  公开号：EP1392348A1

  公开（公告）日：2004-03-03
• METHODS FOR REDUCING GNRH-POSITIVE TUMOR CELL PROLIFERATION
  申请人：VAN GROENINGHEN JOHANNES C.

  公开号：US20100190692A1

  公开（公告）日：2010-07-29

  A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells originating in the brain and/or nervous system and/or the meninges and/or reactive neuroglia cells and/or primitive neuroectodermal tumor cells and/or on Kaposi sarcoma is provided. Furthermore a method for reducing degenerate GnRH-positive tumor cells and/or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and/or GnRH antagonist and/or an erythropoietin agonist, and/or a thrombopoietin agonist, and/or a endothelin antagonist and/or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.
• US7288517B2
  申请人：——

  公开号：US7288517B2

  公开（公告）日：2007-10-30
• [EN] TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISEASES WITH INTERMEDIATE DOSES OF LHRH ANTAGONISTS<br/>[FR] TRAITEMENT DE LA DEMENCE ET DE MALADIES NEURODEGENERATIVES PAR DES DOSES INTERMEDIAIRES D'ANTAGONISTES DE LUTEOLUBERINE
  申请人：ZENTARIS AG

  公开号：WO2002102401A1

  公开（公告）日：2002-12-27

  The present invention relates to the treatment of dementia and neurodegenerative diseases like Alzheimer's disease with intermediate doses of LHRH antagonists which do not cause a castration. A preferred LHRH antagonist is cetrorelix.